At investor event Aktieportföljen Live, on October 15th, Chordate CEO Anders Weilandt talked about the appointment of Partner International Switzerland GmbH as an advisor to find a buyer for the business.
“If we focus on the exit, is it a partner (buyer) within the field of migraine or more of a medtech company or a distributor?”
“We are quite agnostic about who the best buyer could be. The easy answer is the one who pays the most, but it’s somewhere in the area you’re talking about. I would add besides the two obvious segments of the pharma industry and the medtech industry, a portfolio building structure that builds up product portfolio. It could very well be a company or outfit that we are unaware of. We do not really point our advisors in any specific direction. It’s their job, which they are good at, to comb the market for people with the strategic thinking that see a reason to invest in this kind of very clear cut, specific technology, to add to a probably already existing portfolio”, said Anders Weilandt till Aktieportföljen Live.